The Asia Pacific Point-of-Care Molecular Diagnostics Market was valued at $439.7 Million in 2025 and projected to reach to $815.1 Million by 2030, representing a compound annual growth rate of 13.1%. Asia Pacific's point-of-care molecular diagnostics market is positioned for exceptional growth through 2030, driven by substantial healthcare infrastructure investments and rising disease burden across the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Asia Pacific's point-of-care molecular diagnostics market is expanding at 13.1% CAGR, significantly outpacing the global average of 10.5%, reflecting strong regional demand and market maturation.
The region's market is valued at $439.7 million in 2025 and is projected to nearly double to $815.1 million by 2030, demonstrating robust investment potential and sustained growth trajectory.
Rising healthcare infrastructure investments across Asia Pacific are enabling wider deployment of rapid diagnostic technologies in both urban and emerging healthcare settings.
Increasing infectious disease prevalence and growing adoption of rapid diagnostic solutions are key catalysts accelerating market penetration throughout the Asia Pacific region.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SEPSIS (Disease Type) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 10.5% from 2025 to 2030 |
| Largest Segment | RT-PCR (Technology) |
| Market Size Base Year (Billions) | ~USD 4.3 (2025) |
| Revenue Forecast (Billions) | ~USD 7.09 (2030) |
| Segments Covered | Product & Service, Technology, Sample Type, Application, End User, Disease Type |
6 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|---|
| China | USD 376.2 Million |
| Japan | USD 220.5 Million |
| India | USD 113.2 Million |
| Rest Of Asia Pacific | USD 105.3 Million |
Asia Pacific's point-of-care molecular diagnostics market was valued at $439.7 million in 2025 and is projected to reach $815.1 million by 2030.
Asia Pacific's market is growing at a compound annual growth rate (CAGR) of 13.1% from 2025 to 2030, significantly outpacing the global average of 10.5%.
Major growth drivers in Asia Pacific include China, India, Japan, and Southeast Asian nations, where healthcare infrastructure investments and infectious disease prevalence are increasing demand for rapid diagnostics.
Key growth factors include rising healthcare infrastructure investments, increasing infectious disease burden, expanding middle-class populations, government healthcare initiatives, and growing demand for decentralized testing solutions.
Asia Pacific's 13.1% CAGR significantly exceeds the global CAGR of 10.5%, making the region a critical growth engine for the global point-of-care molecular diagnostics market.
The study involved estimating activities to determine the current size of the point-of-care molecular diagnostics market. Exhaustive secondary research was done to collect information on the point-of-care molecular diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the point-of-care molecular diagnostics market.
In the secondary research process, various secondary sources, such as annual reports, press releases, and investor presentations of companies; white papers; certified publications; articles by recognized authors; gold-standard & silver-standard websites; regulatory bodies; and databases like D&B Hoovers, Bloomberg Business, and Factiva, were referred to identify and collect information for this study.
In the primary research process, primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Breakdown of Primaries
To know about the assumptions considered for the study, download the pdf brochure
Both bottom-up and top-down approaches were used to estimate and validate the point-of-care molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in tkehe mart. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Point-of-care molecular diagnostics includes various portable point-of-care devices and assays used by healthcare professionals to detect and diagnose diseases in humans using different techniques to identify and analyze nucleic acids or proteins at the molecular level.
Full forecast, segment splits, and company analysis for all Point-of-Care Molecular Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report